Indeed, in the Sertraline Antidepressant Heart Attack Randomized Trial (SADHART) study, treatment with sertraline resulted in substantially less release of platelet (P-selectin, platelet factor 4, and thromboxane B2) and endothelial markers (vascular cell adhesion molecule-1 and E-selectin) as compared to placebo, in patients that suffered depression post-MI (38). This evidence concerns the gene PF4 and depressive symptom measurement.